Merck, known as MSD outside of the United States and Canada, and VelosBio Inc. announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments. Read more.